AstraZeneca
NICE recommends Benralizumab for Rare Form of Vasculitis
August 15, 2025Medical Communications, Research and Development AstraZeneca, Immunology, National Institute for Health and Care Excellence, vasculitis
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as an add-on treatment for adult …
NICE approves AstraZeneca’s dual immunotherapy for advanced liver cancer
July 30, 2025Medical Communications, Research and Development AstraZeneca, NHS, National Institute for Health and Care Excellence, Oncology, dual immunotherapy, hepatocellular carcinoma, liver cancer
AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence (NICE) for its dual immunotherapy …
Purpose and people: the enduring power of brand and the evolution of employer identity
July 7, 2025Branding, Business Services, Corporate Branding, Medical Communications, Sales and Marketing AstraZeneca, Identity, Inclusion, The Caffeine Partnership, benenden health, branding
Two decades ago, terms like purpose and people were rarely at the forefront of branding conversations. The focus was on …
NHS ConfedExpo 2025: a platform for change in UK health and care
June 24, 2025Medical Communications Accenture, AstraZeneca, Corporate, Excellence in healthcare Partnership (EHP) Awards, Manchester, NHS ConfedExpo, NHS Confederation, NHS England, Novartis UK, Visions4Health
This year’s NHS ConfedExpo took place on 11 to 12 June at Manchester Central, bringing together around 9,000 attendees. Among …
AstraZeneca’s AMPLIFY trial interim analysis demonstrates positive results for Calquence plus venetoclax
July 30, 2024Research and Development AstraZeneca, Haematology, chronic lymphocytic leukaemia, haematology, trial analysis
AstraZeneca has announced positive high-level results from an interim analysis for its AMPLIFY phase 3 trial, combining AstraZeneca’s Calquence (acalabrutinib) …
AstraZeneca’s Tagrisso gains EU approval for lung cancer treatment
July 8, 2024Medical Communications AstraZeneca, Oncology, Tagrisso, lung cancer
AstraZeneca has announced that the EU’s European Commission (EC) has approved Tagrisso (osimertinib), with the addition of pemetrexed and platinum-based …
AstraZeneca’s Tagrisso approved in Japan for lung cancer treatment
June 25, 2024Medical Communications AstraZeneca, Oncology, Tagrisso, chemotherapy, lung cancer
AstraZeneca has announced that Tagrisso (osimertinib) in combination with pemetrexed and platinum-based chemotherapy has been approved in Japan for the …
AstraZeneca’s Imfinzi approved in US for endometrial cancer treatment
June 17, 2024Medical Communications AstraZeneca, Imfinzi, Oncology, chemotherapy, endometrial cancer
AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Imfinzi (durvalumab) in combination with carboplatin and …
AstraZeneca shares results from phase 3 TROPION-Lung01 trial
May 28, 2024Medical Communications AstraZeneca, Daiichi Sankyo, NSCLC, Oncology, clinical trial, datopotamab deruxtecan
AstraZeneca has announced results from the phase 3 TROPION-Lung01 trial of AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan (Dato-DXd). The survival …
Nona Biosciences announced agreement with AstraZeneca for tumour targeted therapies
May 24, 2024Research and Development AstraZeneca, Cancer, Oncology, nona biosciences, targeted therapies
Nona Biosciences and AstraZeneca have announced that the two companies have entered into a license agreement for preclinical monoclonal antibodies, …
AstraZeneca to build $1.5bn ADC facility in Singapore
May 20, 2024Manufacturing and Production ADCs, AstraZeneca, Oncology, antibody drug conjugate, manufacturing
AstraZeneca has announced that it intends to build a $1.5bn manufacturing facility in Singapore, Singapore, for antibody drug conjugates (ADCs), …
AstraZeneca shares results from phase 3 trial of COVID-19 prevention drug
May 17, 2024Research and Development AstraZeneca, COVID-19, Immunology, clinical trial
AstraZeneca has announced positive high-level results from the SUPERNOVA phase 3 trial for a COVID-19 pre-exposure prophylaxis treatment, sipavibart (formerly …
AstraZeneca adds new heart failure target through collaboration with BenevolentAI
May 15, 2024Research and Development AstraZeneca, BenevolentAI, Cardiology, collaboration, heart failure
BenevolentAI has announced that AstraZeneca has added a novel heart failure target to its discovery portfolio following the two companies’ …
AstraZeneca withdraws COVID-19 vaccine Vaxzevria
May 9, 2024Sales and Marketing AstraZeneca, COVID-19, Immunology, thrombosis with thrombocytopenia syndrome
UK-based pharmaceutical company AstraZeneca has announced that is it voluntarily withdrawing its COVID-19 vaccine Vaxzevria due to a drop in …
AstraZeneca shares positive interim results from phase 3 lymphoma trial
May 3, 2024Medical Communications AstraZeneca, Calquence, Oncology, clinical trial, lymphoma
AstraZeneca has announced positive high-level results from an interim analysis of the ECHO phase 3 trial, which assessed Calquence (acalabrutinib) …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
